Lexicon Pharmaceuticals has already thrown in the towel on its commercial efforts after a years-long uphill battle to get its ...

New Delhi: Rahi Sarnobat recalls that autumn day of 2022 with clarity. Indian shooters, following a medalless Tokyo Olympics ...

The state health organisation said it would be looking into Friday’s reports regarding the embezzlement of more than €30 ...

The U.S. FDA smacked Lexicon Pharmaceuticals Inc. with a complete response letter regarding the NDA for Zynquista (sotagliflozin) as an adjunct to insulin therapy for glycemic control in adults with ...

"We are sincerely grateful to the patients and physicians who participated in our Zynquista™ clinical trials, and the broader diabetes community who strongly advocated for Zynquista’s approval," said ...

Lexicon said that its near-term focus will be on its drug candidate LX9211 for diabetic neuropathic pain, with topline Phase ...

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced it has received a complete response letter (CRL) from the U.S. Food and Drug Administration ...

Shares of Vertex Pharmaceuticals Incorporated VRTX were down 11.4% yesterday after the company announced data from a phase II ...

Lack of NaV1.7 activity leads to the inability to sense pain, whereas NaV1.7 gain of function leads to severe pain. Modulation of NaV1.7, therefore, should be an effective mechanism for decreasing ...

The FDA rejected sotagliflozin for type 1 diabetes and CKD. Lexicon will focus on LX9211 for diabetic neuropathic pain, with ...

Richard Lee Flynn III, of Mankato, pleaded guilty to causing great bodily harm to a care center resident by giving him an ...

Sangamo Therapeutics, Inc. has groundbreaking treatments for neuropathic pain and Hemophilia A. Click for my updated look at ...